VivoSeq
Oncology

Pancreatic Ductal Adenocarcinoma (PDAC)

8

Pipeline Programs↗

7

Active Trials↗

4

Companies Involved↗

Pancreatic Ductal Adenocarcinoma (PDAC) is an early-stage landscape with 8 programs across 4 companies. The most active players are Novartis, Imclone, Roche. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

27/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 1I

Imclone

1 program

Phase 2Roche logo

Roche

1 program

Phase 2B

Beijing Daxiang Biotech Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 50% of 8 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting5 · 71%
Not yet recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Recruiting·VVerastem, Inc.·Phase 2·NCT07644559·180 enrolled
A Study on the Consistency Between Patient-Derived Pancreatic Cancer Organoid-on-a-Chip Drug Sensitivity Test Results and Clinical Chemotherapy Efficacy
Recruiting·BBeijing Daxiang Biotech Co., Ltd·N/A·NCT07683845·164 enrolled
A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Recruiting·BBicycleTx Limited·Phase 2·NCT07450859·39 enrolled
A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma
Recruiting·SSOFIE·Phase 3·NCT07217717·200 enrolled
Phase I, Open Label First in Human Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of JFI447 [68Ga]Ga-DFC413, and Compare to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Recruiting·Novartis logoNovartis·Phase 1·NCT07630961·66 enrolled
A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients
Not yet recruiting·FFudan University·Phase 2·NCT07694973·62 enrolled
A Prospective, Single-arm, Ib/II Exploratory Study of Becotatugvedotin(MRG003) in Combination With Gemcitabine for Second-line Advanced Pancreatic Ductal Adenocarcinoma
Not yet recruiting·PPeking Union Medical College Hospital·Preclinical·NCT07685470·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)